FDA Seeks Further Safety Information from Eli Lilly Regarding New Weight Loss Medication Foundayo
The Food and Drug Administration has formally requested that pharmaceutical giant Eli Lilly collect additional long-term safety data concerning its recently approved GLP-1 weight loss tablet, Foundayo. This regulatory request, detailed in an April 1 letter made public by the FDA on Tuesday, highlights ongoing concerns about potential health risks associated with the once-daily pill.
Focus on Potential Health Risks of Orforglipron
Central to the FDA's inquiry is whether Foundayo, which utilizes a novel active ingredient named orforglipron, might be connected to serious adverse effects involving the liver, heart, and gastrointestinal system. The agency has specifically mandated a clinical trial to investigate signals of retained gastric contents and to identify any unexpected serious risks related to major adverse cardiovascular events, drug-induced liver injury, and exposure during lactation.
The FDA emphasized that only a clinical trial, rather than observational studies, would be sufficient to adequately assess these potential safety issues. Eli Lilly has been given until the end of April to complete this trial and until July to submit a comprehensive final report to regulators.
Regulatory Context and Market Position
Foundayo received FDA approval earlier this month under a fast-track program that relied on 72-week Phase 3 trial data. However, the agency now requires years-long data to fully understand all possible long-term risks. This development represents a significant regulatory hurdle for the medication, which is only the second GLP-1 weight loss pill to reach the U.S. market, following Novo Nordisk's Wegovy pill approved in December.
Notably, the FDA did not request similar additional safety data for Wegovy, as its active ingredient, semaglutide, has been approved since 2017 and has undergone more extensive testing than orforglipron.
Company Response and Patient Safety Considerations
Eli Lilly has stated that patient safety remains its top priority, with a spokesperson affirming that the company actively monitors, evaluates, and reports safety information for all its medicines. It remains uncertain whether Foundayo might require future modifications based on the outcomes of the additional clinical trial requested by the FDA.
The company has already conducted shorter-term research involving patients with obesity and type 2 diabetes who face elevated cardiovascular risks. Phase 3 results previously shared by Eli Lilly demonstrated significant weight loss efficacy, with adults taking the highest-approved dose for weight loss purposes shedding an average of 17.2 pounds over 72 weeks.
Broader Implications for Weight Loss Medication Market
Weight loss pills like Foundayo were developed to provide easier administration compared to injectable GLP-1 drugs and to expand patient access to these treatments. Pharmaceutical companies are also working to make these medications more affordable, as GLP-1 injectables can cost thousands of dollars monthly without insurance coverage.
While out-of-pocket prices for weight loss pills are generally lower than injections, they may still amount to hundreds of dollars. For instance, the lowest dose Wegovy pill costs approximately $25 monthly for insured patients and $149 without insurance, with Eli Lilly indicating similar pricing for 0.8 milligrams of Foundayo.
Most weight loss medications come with known side effects such as nausea and muscle loss, and drug manufacturers continue to research ways to improve these treatments and reduce patient discontinuation rates. The FDA's request for additional safety data on Foundayo underscores the ongoing regulatory scrutiny facing new weight loss pharmaceuticals as they enter the competitive market.
